Real-world effectiveness of aromatase inhibitors and fulvestrant in HR+/HER2- advanced breast cancer: a snapshot of the last two years before conventional use of CDK 4/6 inhibitors in a Portuguese institution

References

• Aguiar, J. P., Cardoso Borges, F., Murteira, R., Ramos, C., Gouveia, E., Passos, M. J., Miranda, A., & da Costa, F. A. (2018). Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma. International Journal of Clinical Pharmacy, 40(4), 852–861. https://doi.org/10.1007/s11096-018-0665-1
   PubMed Web of Science ®Google Scholar
• Akram, M., Iqbal, M., Daniyal, M., & Khan, A. U. (2017). Awareness and current knowledge of breast cancer. Biological Research, 50(1), 1–23. https://doi.org/10.1186/s40659-017-0140-9
   PubMedGoogle Scholar
• Alves da Costa, F., Cardoso Borges, F., Ramos, A., Mayer, A., Brito, C., Ramos, C., Bernardo, C., Cossito, M., Furtado, C., Ferreira, A. R., Martins-Branco, D., da Costa Miranda, A., & Lourenço, A. (2023). Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: Implications for clinical practice. Breast Cancer Research, 25(1), 1–11. https://doi.org/10.1186/s13058-023-01678-5
   PubMed Web of Science ®Google Scholar
• Assembleia da República. (2017). Law n.º 53/2017, 14th of July [Creates and regulates the National Cancer Registry]. Diário da República n.º 135/2017, Série I 2017-07-14, 3739–3743.
   Google Scholar
• Battisti, N., De Glas, N., Sedrak, M., Loh, K., Liposits, G., Soto-Perez-de-Celis, E., Krok-Schoen, J., Menjak, I. B., & Ring, A. (2018). Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper. Therapeutic Advances in Medical Oncology, 10, 1–26. https://doi.org/10.1177/1758835918809610
   Web of Science ®Google Scholar
• Bjartell, A., Lumen, N., Maroto, P., Paiss, T., Gomez-Veiga, F., Birtle, A., Kramer, G., Kalinka, E., Spaëth, D., Feyerabend, S., Matveev, V., Lefresne, F., Lukac, M., Wapenaar, R., Costa, L., & Chowdhury, S. (2021). Real-world safety and efficacy outcomes with Abiraterone acetate plus prednisone or prednisolone as the first- or second-line treatment for metastatic castration-resistant prostate cancer: Data from the prostate cancer registry. Targeted Oncology, 16(3), 357–367. https://doi.org/10.1007/s11523-021-00807-4
   PubMed Web of Science ®Google Scholar
• Borges, F. C., Ramos, C., Ramos, A., Mendes, G. P., Murteira, R., Soares, P., Furtado, C., Miranda, A. C., & Costa, F. A. (2020). Monitoring real-life utilization of pembrolizumab in advanced melanoma using the Portuguese National Cancer Registry. Pharmacoepidemiology and Drug Safety, 30(3), 342–349. https://doi.org/10.1002/pds.5163
   PubMed Web of Science ®Google Scholar
• Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., Boyle, F., Cardoso, M.-J., Carey, L. A., Cortés, J., El Saghir, N. S., Elzayat, M., Eniu, A., Fallowfield, L., Francis, P. A., … Winer, E. P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.09.010
   Web of Science ®Google Scholar
• Cardoso Borges, F., Alves da Costa, F., Ramos, A., Ramos, C., Bernardo, C., Brito, C., Mayer-da-Silva, A., Furtado, C., Ferreira, A. R., Martins-Branco, D., Miranda, A., & Lourenço, A. (2022). Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study. The Breast, 62, 135–143. https://doi.org/10.1016/j.breast.2022.02.005
   PubMed Web of Science ®Google Scholar
• Carson, E., & Dear, R. (2019). Advanced breast cancer: An update to systemic therapy. Australian Journal of General Practice, 48(5), 278–283. https://doi.org/10.31128/AJGP-10-18-4729
   PubMed Web of Science ®Google Scholar
• Cheung, K. L. (2007). Endocrine therapy for breast cancer: An overview. The Breast, 16(4), 327–343. https://doi.org/10.1016/j.breast.2007.03.004
   PubMed Web of Science ®Google Scholar
• Costa, F. A., Ramos, C., Murteira, R., Almodovar, T., Passos-Coelho, J. L., Carvalho, M. I., Costa, L., & Miranda, A. C. (2019). The cancer registry as an ally in monitoring treatment effectiveness. Pulmonology, 25(1), 3–8. https://doi.org/10.1016/j.pulmoe.2018.05.007
   PubMed Web of Science ®Google Scholar
• Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., Pendergrass, K., Garnett, S., Lindemann, J. P. O., Sapunar, F., & Martin, M. (2010). Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Journal of Clinical Oncology, 28(30), 4594–4600. https://doi.org/10.1200/JCO.2010.28.8415
   PubMed Web of Science ®Google Scholar
• Ding, W., Li, Z., Wang, C., Ruan, G. D., Chen, L. P., & Tu, C. (2018). The CDK4/6 inhibitor in HR-positive advanced breast cancer. Medicine (United States), 97(20). https://doi.org/10.1097/MD.0000000000010746
   Google Scholar
• Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J. (2016). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375(20), 1925–1936. https://doi.org/10.1056/NEJMoa1607303
   PubMed Web of Science ®Google Scholar
• Finn, R. S., Rugo, H. S., Dieras, V. C., Harbeck, N., Im, S.-A., Gelmon, K. A., Walshe, J. M., Martin, M., Chavez Mac Gregor, M., Bananis, E., Gauthier, E. R., Lu, D. R., Kim, S., & Slamon, D. J. (2022). Overall survival (OS) with first-line palbociclib plus letrozole (PAL + LET) versus placebo plus letrozole (PBO + LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): analyses. Journal of Clinical Oncology, 40(17_suppl), LBA1003–LBA1003. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1003
   Web of Science ®Google Scholar
• Gluck, S., Bonneterre, J., Buzdar, A., Nabholtz, J. M., Robertson, J., Thrlimann, B., … Webster, A. (2002). Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma (multiple letters). Cancer, 95(11), 2442–2443. https://doi.org/10.1002/cncr.10962
   PubMed Web of Science ®Google Scholar
• Gobbini, E., Ezzalfani, M., Dieras, V., Bachelot, T., Brain, E., Debled, M., Jacot, W., Mouret-Reynier, M. A., Goncalves, A., Dalenc, F., Patsouris, A., Ferrero, J. M., Levy, C., Lorgis, V., Vanlemmens, L., Lefeuvre-Plesse, C., Mathoulin-Pelissier, S., Petit, T., Uwer, L., … Delaloge, S. (2018). Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. European Journal of Cancer, 96, 17–24. https://doi.org/10.1016/j.ejca.2018.03.015
   PubMed Web of Science ®Google Scholar
• Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020). Overcoming endocrine resistance in breast cancer. Cancer Cell, 37(4), 496–513. https://doi.org/10.1016/j.ccell.2020.03.009
   PubMed Web of Science ®Google Scholar
• Howlader, N., Noone, A. M., & Krapcho, M. (2016). SEER cancer statistics review, 1975–2013. National Cancer Institute. Retrieved October 6, 2020, from https://seer.cancer.gov/archive/csr/1975_2013/results_merged/sect_04_breast.pdf
   Google Scholar
• International Agency for Research on Cancer. (1991). Cancer registration: Principles and methods. In IARC scientific publications. https://doi.org/10.2307/1533655
   Google Scholar
• Karim, S., Zhang-Salomans, J., Biagi, J. J., Asmis, T., & Booth, C. M. (2018). Uptake and effectiveness of FOLFIRINOX for advanced pancreatic cancer: A population-based study. Clinical Oncology, 30(1), e16–e21. https://doi.org/10.1016/j.clon.2017.10.017
   PubMed Web of Science ®Google Scholar
• Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., Fowst, C., Polli, A., di Salle, E., Arkhipov, A., Piscitelli, G., Miller, L. L., & Massimini, G. (2000). Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. Journal of Clinical Oncology, 18(7), 1399–1411. https://doi.org/10.1200/JCO.2000.18.7.1399
   PubMed Web of Science ®Google Scholar
• Liu, X., Qu, H., Cao, W., Wang, Y., Ma, Z., Li, F., & Wang, H. (2013). Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy. Endocrine Journal, 60(6), 819–828. https://doi.org/10.1507/endocrj.EJ12-0434
   PubMed Web of Science ®Google Scholar
• Martínez Marín, V., Muñoz Martín, A. J., Viñuela Benéitez, M. C., García Alfonso, P., Alonso Muñoz, A., & Pérez Manga, G. (2009). Tratamiento con fulvestrant en mujeres posmenopáusicas con cáncer de mama avanzado tras tratamiento hormonal previo. Medicina Clinica, 133(10), 371–374. https://doi.org/10.1016/j.medcli.2008.11.029
   PubMedGoogle Scholar
• McAndrew, N. P., & Finn, R. S. (2020). Management of ER positive metastatic breast cancer. Seminars in Oncology, 47(5), 270–277. https://doi.org/10.1053/j.seminoncol.2020.07.005
   PubMed Web of Science ®Google Scholar
• Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jaenicke, F., Pluzanska, A., Dank, M., Becquart, D., Bapsy, P. P., Salminen, E., Snyder, R., Chaudri-Ross, H., Lang, R., Wyld, P., & Bhatnagar, A. (2003). Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology, 21(11), 2101–2109. https://doi.org/10.1200/JCO.2003.04.194
   PubMed Web of Science ®Google Scholar
• Murteira, R., Borges, F. C., Mendes, G. P., Ramos, C., Ramos, A., Soares, P., Furtado, C., Miranda, A., & da Costa, F. A. (2020). Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: A population-based cohort study. Pharmacoepidemiology and Drug Safety, 29(10), 1295–1302. https://doi.org/10.1002/pds.5091
   PubMed Web of Science ®Google Scholar
• Steger, G. G., Bartsch, R., Wenzel, C., Pluschnig, U., Hussian, D., Sevelda, U., Locker, G. J., Gnant, M. F., Jakesz, R., & Zielinski, C. C. (2005). Fulvestrant (‘Faslodex’) in pre-treated patients with advanced breast cancer: A single-centre experience. European Journal of Cancer, 41(17), 2655–2661. https://doi.org/10.1016/j.ejca.2005.07.016
   PubMed Web of Science ®Google Scholar
• Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., André, F., Puyana Theall, K., Huang, X., Giorgetti, C., Huang Bartlett, C., & Cristofanilli, M. (2018). Overall survival with palbociclib and fulvestrant in advanced breast cancer. New England Journal of Medicine, 379(20), 1926–1936. https://doi.org/10.1056/NEJMoa1810527
   PubMed Web of Science ®Google Scholar
• von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007). The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet (London, England), 370(9596), 1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2020). Globocan 2020. https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
   Google Scholar
• Yoo, C., Kim, S. B., Ahn, J. H., Jung, K. H., Ahn, Y., Gong, G., Kim, H.-H., Kim, H.-J., Son, B.-H., & Ahn, S. H. (2011). Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: A preliminary report. Journal of Breast Cancer, 14(2), 135–139. https://doi.org/10.4048/jbc.2011.14.2.135
   PubMed Web of Science ®Google Scholar
• Zhang, J., Huang, Y., Wang, C., He, Y., Zheng, S., & Wu, K. (2017). Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. Medicine (United States), 96(33), 1–6. https://doi.org/10.1097/MD.0000000000007846
   Google Scholar